What is the appropriate dosing, contraindications, and monitoring for rasagiline in Parkinson disease?

Rasagiline Dosing, Contraindications, and Monitoring in Parkinson's Disease

Rasagiline is administered at 1 mg once daily as monotherapy or adjunct therapy without levodopa, and 0.5 mg once daily as adjunct to levodopa (with option to increase to 1 mg daily if needed for clinical response). 1

Dosing Regimens

Standard Dosing

• Monotherapy in early PD: 1 mg orally once daily 1, 2
• Adjunct therapy without levodopa: 1 mg orally once daily 1
• Adjunct therapy with levodopa: Start at 0.5 mg once daily; may increase to 1 mg daily based on clinical response 1, 3

Dose Adjustments Required

• Patients taking CYP1A2 inhibitors (e.g., ciprofloxacin): Maximum dose 0.5 mg once daily 1
• Mild hepatic impairment: Maximum dose 0.5 mg once daily 1, 2
• Moderate to severe hepatic impairment: Rasagiline should not be used 1

Pharmacokinetic Properties

• Oral bioavailability is 35% 2
• Time to maximum concentration (Tmax): 0.5-1 hours 2
• Half-life: 1.5-3.5 hours 2
• Undergoes extensive hepatic metabolism primarily via CYP1A2 1, 2

Absolute Contraindications

Rasagiline is contraindicated with concomitant use of the following medications: 1

• Meperidine (risk of serotonin syndrome)
• Tramadol
• Methadone
• Propoxyphene
• Dextromethorphan (risk of psychosis or bizarre behavior)
• St. John's wort
• Cyclobenzaprine
• Any other MAO inhibitor (selective or non-selective) - risk of non-selective MAO inhibition and hypertensive crisis

Major Warnings and Precautions

Hypertensive Reactions

• May cause severe hypertensive syndromes at recommended doses 1
• However, tyramine challenge studies demonstrate that rasagiline at approved doses (up to 1 mg/day) is selective for MAO-B and does not require dietary tyramine restrictions 4
• Clinical trials involving 2066 rasagiline-treated patients did not require dietary tyramine restriction and demonstrated safety 4

Serotonin Syndrome

• Risk when used with antidepressants; avoid concomitant use with certain antidepressants 1
• Meperidine specifically contraindicated due to serotonin syndrome risk 1

Neuropsychiatric Effects

• Somnolence and sudden sleep onset: May cause falling asleep during activities of daily living and daytime drowsiness 1
• Hallucinations and psychotic-like behavior: Monitor for emergence of these symptoms 1
• Impulse control/compulsive behaviors: Screen for development of pathological gambling, hypersexuality, compulsive shopping, or binge eating 1

Motor Complications

• Dyskinesia: May cause or exacerbate dyskinesia, particularly when used as adjunct to levodopa; decreasing levodopa dose may lessen or eliminate this effect 1
• Hypotension: May cause orthostatic hypotension 1

Withdrawal Considerations

• Withdrawal-emergent hyperpyrexia and confusion: Avoid abrupt discontinuation 1

Monitoring Parameters

Clinical Efficacy Monitoring

• "Off" time reduction: In advanced PD patients on levodopa, rasagiline reduces mean daily "off" time by approximately 1.2-1.7 hours compared to placebo 5, 6
• Motor function: Monitor using Unified Parkinson's Disease Rating Scale scores 3, 6

Safety Monitoring

• Blood pressure: Monitor for hypertension and orthostatic hypotension 1
• Mental status: Screen for hallucinations, psychotic symptoms, confusion, and impulse control disorders 1
• Motor symptoms: Assess for dyskinesia development or worsening 1
• Hepatic function: Particularly important in patients with pre-existing liver disease 1, 2
• Somnolence: Evaluate for excessive daytime sleepiness and sudden sleep episodes 1

Drug Interaction Monitoring

• CYP1A2 inhibitors: Dose reduction required when co-administered 1
• Sympathomimetic amines: Contraindications regarding concomitant use with sympathomimetic amines have been removed from US labeling due to demonstrated MAO-B selectivity at approved doses 4
• Anesthesia: Previous contraindications regarding sympathomimetic vasopressors during anesthesia have been removed 4

Common Adverse Reactions

As Monotherapy (≥3% and greater than placebo)

• Flu syndrome, arthralgia, depression, dyspepsia 1

As Adjunct Without Levodopa (≥3% and greater than placebo)

• Peripheral edema, fall, arthralgia, cough, insomnia 1

As Adjunct to Levodopa (≥3% and greater than placebo)

• Dyskinesia, accidental injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, fall, tenosynovitis 1

Clinical Efficacy Evidence

Rasagiline demonstrates clinically meaningful benefit in both early and advanced PD. In early PD monotherapy, the adjusted effect size for total UPDRS score after 26 weeks was -4.20 (95% CI, -5.66 to -2.73) versus placebo (p < 0.001) 3. In advanced PD with motor fluctuations, rasagiline reduces "off" time by 1.18-1.7 hours compared to placebo (p ≤ 0.001) 3, 6.

Key Clinical Advantages

• Once-daily dosing: Convenient administration schedule 5
• No amphetamine metabolites: Unlike selegiline, rasagiline is not metabolized to potentially toxic amphetamine derivatives 2
• No dietary restrictions: Tyramine restrictions are not ordinarily required at recommended doses 4
• Well tolerated: Demonstrated safety in both younger (<70 years) and older (≥70 years) patients 3